Volume 2015, Issue 5
  • ISSN: 2305-7823
  • EISSN:


The impetus for developing drug-eluting bioresorbable scaffolds (BRS) has been driven by the need for elastic and transient platforms instead of stiff and permanent metallic implants in diseased coronary anatomies. This endeavor would prevent acute recoil or occlusion, allow sealing of post-procedural dissections following acute barotrauma, provide inhibition of in-segment restenosis through efficient drug-elution and would further prepare the vessel to enter a reparative phase following scaffold resorption. Biocorrodible metallic platforms have been introduced as alternatives to bioresorbable polymeric scaffolds for the treatment of significant atherosclerosis and in view of the body of evidence derived from recent clinical trials we elaborate on the clinical safety and efficacy of these devices in interventional cardiology.


Article metrics loading...

Loading full text...

Full text loading...



  1. Gogas BD. Bioresorbable scaffolds for percutaneous coronary interventions. Glob Cardiol Sci Pract. 2014; 2014:4:409427, doi:10.5339/gcsp.2014.55.
    [Google Scholar]
  2. Sigwart U. Treatment of coronary artery disease from the inside: Light at the end of the tunnel? Glob Cardiol Sci Pract. 2015; 53:, doi:10.5339/gcsp.2015.53 .
    [Google Scholar]
  3. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Böse D, Koolen J, Lüscher TF, Weissman N, Waksman R. PROGRESS-AMS (clinical performance and angiographic results of coronary stenting with absorbable metal stents) investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet. 2007; 369:9576:18691875, doi:10.1016/S0140-6736(07)60853-8 .
    [Google Scholar]
  4. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013; 381:9869:836844, doi:10.1016/S0140-6736(12)61765-6 .
    [Google Scholar]
  5. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann F-J, Kaiser C, Eeckhout E, Lim ST, Escaned J, Garcia-Garcia HM, Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. October 2015;. doi:10.1016/S0140-6736(15)00447-X .
    [Google Scholar]
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error